Last updated: February 23, 2026
What is Golytely?
Golytely is a osmotic laxative with the active ingredient polyethylene glycol-electrolyte solution (PEG-ES). It is used primarily for bowel prep before colonoscopy procedures. Approved by the FDA in 1994, Golytely is marketed as a prescription product, with some generic equivalents available.
Market Overview
Therapeutic Area and Indications
Golytely falls within the bowel cleansing agent category. The primary indication is preparing patients for colonoscopy. The drug's utility extends across screening, diagnostic, and some therapeutic procedures involving the colon.
Market Size
The global bowel cleansing market in 2022 was valued at approximately USD 770 million. The segment is projected to grow at a compound annual growth rate (CAGR) of 5.3% reaching USD 1.05 billion by 2027. The growth drivers are increasing colorectal cancer screening programs and rising awareness of colon health.
Regional Market Breakdown
| Region |
Market Share (2022) |
CAGR (2023-2027) |
Key Factors |
| North America |
55% |
4.8% |
High screening rates, established healthcare system |
| Europe |
25% |
5.2% |
Growing screening initiatives |
| Asia-Pacific |
12% |
6.0% |
Increasing healthcare access, aging population |
| Rest of World |
8% |
5.5% |
Expanding healthcare infrastructure |
Competitive Landscape
Major competitors include other PEG-based formulations and non-PEG bowel prep solutions:
- Miralax (OTC, non-prescription alternative)
- Sutab (sodium sulfate-based solution)
- Clensia (co-lyte oral solution)
- Generic PEG-ES solutions
Golytely's patent expired in 2014, elevating generics' market share. The brand remains preferred for its established efficacy and tolerability.
Market Drivers
- Increasing prevalence of colorectal cancer (CRC). In 2020, CRC accounted for 10% of all cancers worldwide [1].
- Rising screening rates driven by guidelines recommending colonoscopy starting at age 45-50.
- Growing elderly population, which is at higher risk for CRC.
- Patent expiries and availability of generics driving down prices.
Challenges
- Patient preferences shifting toward lower-volume or more palatable preparations.
- Competition from OTC formulations.
- Concerns over tolerability and electrolyte disturbances in certain populations.
Sales Projections (2023–2027)
Assuming a base year of 2022, with an estimated USD 400 million in global sales for Golytely and its generics, the following projections are based on industry growth rates and market dynamics:
| Year |
Projected Sales (USD million) |
Assumptions |
| 2023 |
420 |
Modest growth, continued adoption of screening |
| 2024 |
440 |
Increased penetration, generic growth |
| 2025 |
470 |
Rising screening, population aging |
| 2026 |
500 |
Healthcare access improvements, new markets |
| 2027 |
530 |
Market expansion, increased awareness |
The annual growth rate averages around 5%, aligning with industry CAGR estimates.
Regulatory and Patent Landscape Impact
The expiration of Golytely's patent and the entry of generics have increased accessibility and reduced prices, encouraging wider use. This expansion is expected to sustain sales growth, supported by continuing clinical guidelines endorsing colonoscopy screening.
Key Market Opportunities
- Development of novel formulations with improved taste profiles.
- Expansion into emerging markets with expanding screening programs.
- Positioning across various age groups, including younger patients requiring colonoscopy.
- Potential combination products to improve compliance.
Key Takeaways
- The global bowel cleansing market, including Golytely, is projected to grow at approximately 5.3% annually to 2027.
- North America dominates the market due to high screening rates and healthcare infrastructure.
- Generics increased Golytely’s accessibility but face challenges from patient preferences and alternative preparations.
- Sales of Golytely and equivalents are expected to reach USD 530 million globally by 2027.
- Market growth relies heavily on increasing screening adherence, demographic shifts, and regulatory policies.
FAQ
1. What factors influence Golytely’s market share?
Pricing, formulary coverage, patient acceptance, and competition from alternatives like OTC products or other bowel prep solutions influence market share.
2. How will patent expiration affect Golytely sales?
Patent expiry led to increased generic competition, reducing prices and expanding access, which supports broader usage rather than declines in sales.
3. Are new formulations impacting Golytely’s market?
Yes. New formulations offering improved taste and tolerability aim to capture unmet needs, potentially threatening Golytely's market dominance.
4. What regional markets present the highest growth potential?
Asia-Pacific and Latin America exhibit the highest growth rates due to expanding healthcare access and awareness.
5. How might regulatory changes influence future sales?
Guidelines promoting earlier screening and reimbursement policies can boost demand, while restrictive regulations or safety concerns may limit growth.
References
- American Cancer Society. (2022). Colorectal Cancer Facts & Figures 2022–2024. Retrieved from https://www.cancer.org
